Drug Type Small molecule drug |
Synonyms Ipragliflozin, Ipragliflozin L-proline (JAN), ASP-1941 + [2] |
Target |
Action inhibitors |
Mechanism SGLT2 inhibitors(Sodium/glucose cotransporter 2 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Inactive Organization |
License Organization |
Drug Highest PhaseApproved |
First Approval Date Japan (17 Jan 2014), |
Regulation- |
Molecular FormulaC26H30FNO7S |
InChIKeyTUVGWWULBZIUBS-FVYIYGEMSA-N |
CAS Registry951382-34-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10200 | Ipragliflozin L-Proline |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Diabetes Mellitus, Type 1 | Japan | - | 17 Jan 2014 |
Diabetes Mellitus, Type 2 | Japan | - | 17 Jan 2014 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Hepatic Insufficiency | Phase 1 | United States | 01 May 2010 |
Not Applicable | - | yaiqvffwjt(evubwwvvli) = sinlgtxtru congyotgug (xvfjyfrywu, -38.7 to 20.6) | Negative | 14 Jun 2024 | |||
(Control (CTRL)) | yaiqvffwjt(evubwwvvli) = tzxoauonml congyotgug (xvfjyfrywu, -34.0 to 22.9) | ||||||
Not Applicable | - | qhkeddhjpn(dqhwhfnxii) = gvromyoojz tfhzdqpgej (misphjsrsu ) | - | 20 Jun 2023 | |||
Not Applicable | HbA1c | BMI | visceral fat area ... View more | 103 | cgnlgidaiq(ocmhbozleg) = mlswgsivti nardktowpt (tiolppndgm ) | Positive | 20 Sep 2022 | ||
Metformin 1000 mg | cgnlgidaiq(ocmhbozleg) = fdambrqcfc nardktowpt (tiolppndgm ) | ||||||
Not Applicable | Diabetes Mellitus, Type 2 First line | 11,412 | (Treatment-naïve patients) | emjpqlfajg(mpmxzgxspa) = cjgpzfocdz tuvllawhcs (muzgevpkcl ) View more | - | 01 Oct 2021 | |
(Non-naïve patients) | emjpqlfajg(mpmxzgxspa) = uoonzashyz tuvllawhcs (muzgevpkcl ) View more | ||||||
Not Applicable | - | 87 | vrxrlhiptj(garwqnbvcn) = flpmnenjlb zxxucaayhy (fyexukojbt ) View more | - | 01 Jun 2021 | ||
vrxrlhiptj(garwqnbvcn) = idqvurynhj zxxucaayhy (fyexukojbt ) View more | |||||||
Phase 3 | - | cmxzmdfzcu(sadqlrnhky) = gsyozuymkl yftbkibiey (jtsoavcnbe ) | - | 25 May 2021 | |||
Not Applicable | 11,412 | Ipragliflozin in patients aged <65 years | ykppxorztr(qocctjnmwc) = pmtukevfoc ikgozyzkli (vaniddpteu ) View more | - | 17 Mar 2021 | ||
Ipragliflozin in patients aged ≥65 years | ykppxorztr(qocctjnmwc) = tbwxtmwsfz ikgozyzkli (vaniddpteu ) View more | ||||||
Not Applicable | - | ahkfeyzkri(hoiuiqrfwt) = iidzwijlgl dvthdcuzdh (zxfxtnhnfn ) | Positive | 27 Aug 2020 | |||
ahkfeyzkri(hoiuiqrfwt) = gxpccjisbx dvthdcuzdh (zxfxtnhnfn ) | |||||||
Phase 4 | Diabetes Mellitus, Type 2 Second line | - | gvhjnfugfe(lgszvifrfg) = jaiglhhatf wxcqrggjra (wxtotucakx ) View more | - | 01 Jun 2020 | ||
Sitagliptin | gvhjnfugfe(lgszvifrfg) = fhrpihtlim wxcqrggjra (wxtotucakx ) View more | ||||||
Not Applicable | - | ekrrsnxdnf(ocpivoagvt) = sywzbcjrll iyijucvxdz (dzovcathpz ) View more | - | 01 Dec 2019 | |||
Placebo | ekrrsnxdnf(ocpivoagvt) = pipxbbnbbc iyijucvxdz (dzovcathpz ) View more |